Skip to main content
Erschienen in: Diabetologia 12/2006

01.12.2006 | Article

Comparison of different definitions of the metabolic syndrome in relation to cardiovascular mortality in European men and women

verfasst von: Q. Qiao, The DECODE Study Group

Erschienen in: Diabetologia | Ausgabe 12/2006

Einloggen, um Zugang zu erhalten

Abstract

Aims/hypothesis

We estimated cardiovascular disease (CVD) mortality in individuals with the metabolic syndrome on the basis of different definitions.

Methods

We collaboratively analysed data from 4,715 men and 5,554 women, who were aged 30 to 89 years, had a maximum follow-up of 7 to 16 years, and were drawn from nine European population-based cohorts. Cox regression analysis with age as time scale was performed to estimate hazard ratio (HR) for mortality, adjusting for cohort, serum total cholesterol and smoking.

Results

The prevalence of the metabolic syndrome according to definitions of WHO, the National Cholesterol Education Program (NCEP), NCEP revised and the International Diabetes Federation (IDF) was 27.0%, 25.9%, 32.2% and 35.9% respectively in men and 19.7%, 23.4%, 28.5% and 34.1% respectively in women. The corresponding HRs (95% CIs) for CVD mortality were 2.09 (1.59–2.76), 1.74 (1.31–2.30), 1.72 (1.31–2.26) and 1.51 (1.15–1.99) in men, and 1.60 (1.01–2.51), 1.39 (0.89–2.18), 1.09 (0.70–1.69) and 1.53 (0.99–2.36) in women. The paired homogeneity test showed that in men the HR was higher with the WHO definition than with the IDF definition (p=0.03). In women the HR was lower with the revised NCEP definitions than with either the WHO (p=0.02) or the IDF (p=0.01) definitions. With a few exceptions, HRs for full definitions of the syndrome were not significantly different from those for their single components.

Conclusions/interpretation

Metabolic syndrome by the four definitions predicted CVD mortality in men, but the prediction was weak in women. Further research is required on the utility of definitions of the metabolic syndrome above and beyond that of its single components and in individual CVD risk stratification, particularly with regard to sex difference in the prediction.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Alberti KG, Zimmet PZ (1998) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15:539–553PubMedCrossRef Alberti KG, Zimmet PZ (1998) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15:539–553PubMedCrossRef
2.
Zurück zum Zitat World Health Organization Consultation (1999) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Report No. 99.2. WHO, Geneva World Health Organization Consultation (1999) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Report No. 99.2. WHO, Geneva
3.
Zurück zum Zitat Balkau B, Charles MA (1999) Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med 16:442–443PubMedCrossRef Balkau B, Charles MA (1999) Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med 16:442–443PubMedCrossRef
4.
Zurück zum Zitat Adult Treatment Panel III (2002) Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 106:3143–3421 Adult Treatment Panel III (2002) Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 106:3143–3421
5.
Zurück zum Zitat Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001) Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285:2486–2497CrossRef Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001) Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285:2486–2497CrossRef
6.
Zurück zum Zitat Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C (2004) Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Arterioscler Thromb Vasc Biol 24:e13–e18PubMedCrossRef Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C (2004) Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Arterioscler Thromb Vasc Biol 24:e13–e18PubMedCrossRef
7.
Zurück zum Zitat Bloomgarden ZT (2003) American Association of Clinical Endocrinologists (AACE) Consensus Conference on the Insulin Resistance Syndrome: 25–26 August 2002, Washington, DC. Diabetes Care 26:933–939PubMed Bloomgarden ZT (2003) American Association of Clinical Endocrinologists (AACE) Consensus Conference on the Insulin Resistance Syndrome: 25–26 August 2002, Washington, DC. Diabetes Care 26:933–939PubMed
8.
Zurück zum Zitat American College of Endocrinology Task Force on the Insulin Resistance Syndrome (2003) American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract 9:237–252 American College of Endocrinology Task Force on the Insulin Resistance Syndrome (2003) American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract 9:237–252
9.
Zurück zum Zitat Alberti KG, Zimmet P, Shaw J (2005) The metabolic syndrome—a new worldwide definition. Lancet 366:1059–1062PubMedCrossRef Alberti KG, Zimmet P, Shaw J (2005) The metabolic syndrome—a new worldwide definition. Lancet 366:1059–1062PubMedCrossRef
10.
Zurück zum Zitat Alberti KGMM, Zimmet P, Shaw J (2006) Metabolic syndrome—a new world-wide definition. A consensus statement from the International Diabetes Federation. Diabet Med 23:469–480PubMedCrossRef Alberti KGMM, Zimmet P, Shaw J (2006) Metabolic syndrome—a new world-wide definition. A consensus statement from the International Diabetes Federation. Diabet Med 23:469–480PubMedCrossRef
11.
Zurück zum Zitat Ford ES (2005) Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care 28:1769–1778PubMed Ford ES (2005) Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care 28:1769–1778PubMed
12.
Zurück zum Zitat Lawlor DA, Smith GD, Ebrahim S (2006) Does the new International Diabetes Federation definition of the metabolic syndrome predict CHD any more strongly than older definitions? Findings from the British Women’s Heart and Health Study. Diabetologia 49:41–48PubMedCrossRef Lawlor DA, Smith GD, Ebrahim S (2006) Does the new International Diabetes Federation definition of the metabolic syndrome predict CHD any more strongly than older definitions? Findings from the British Women’s Heart and Health Study. Diabetologia 49:41–48PubMedCrossRef
13.
Zurück zum Zitat The DECODE Study Group (1999) Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 354:617–621CrossRef The DECODE Study Group (1999) Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 354:617–621CrossRef
14.
Zurück zum Zitat The DECODE Study Group (1998) Will new diagnostic criteria for diabetes mellitus change phenotype of patients with diabetes? Reanalysis of European epidemiological data. DECODE Study Group on behalf of the European Diabetes Epidemiology Study Group. Br Med J 317:371–375 The DECODE Study Group (1998) Will new diagnostic criteria for diabetes mellitus change phenotype of patients with diabetes? Reanalysis of European epidemiological data. DECODE Study Group on behalf of the European Diabetes Epidemiology Study Group. Br Med J 317:371–375
15.
Zurück zum Zitat The DECODE Study Group (2003) Is the current definition for diabetes relevant to mortality risk from all-cause, cardiovascular and non-cardiovascular disease? Diabetes Care 26:688–696 The DECODE Study Group (2003) Is the current definition for diabetes relevant to mortality risk from all-cause, cardiovascular and non-cardiovascular disease? Diabetes Care 26:688–696
16.
Zurück zum Zitat The DECODE Study Group (2001) Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 161:397–405CrossRef The DECODE Study Group (2001) Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 161:397–405CrossRef
17.
Zurück zum Zitat The DECODE Study Group (2004) Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med 164:1066–1076CrossRef The DECODE Study Group (2004) Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med 164:1066–1076CrossRef
18.
Zurück zum Zitat The DECODE Study Group (2004) Plasma insulin and cardiovascular mortality in non-diabetic European men and women: a meta-analysis of data from eleven prospective studies. Diabetologia 47:1245–1256CrossRef The DECODE Study Group (2004) Plasma insulin and cardiovascular mortality in non-diabetic European men and women: a meta-analysis of data from eleven prospective studies. Diabetologia 47:1245–1256CrossRef
19.
Zurück zum Zitat Fleiss JL (1993) The statistical basis of meta-analysis. Stat Methods Med Res 2:121–145PubMed Fleiss JL (1993) The statistical basis of meta-analysis. Stat Methods Med Res 2:121–145PubMed
20.
Zurück zum Zitat Davidson AC, Hinkley DV (1997) Bootstrap methods and their application. Cambridge University Press, Cambridge Davidson AC, Hinkley DV (1997) Bootstrap methods and their application. Cambridge University Press, Cambridge
21.
Zurück zum Zitat Bonora E, Kiechl S, Willeit J et al (2003) Carotid atherosclerosis and coronary heart disease in the metabolic syndrome: prospective data from the Bruneck study. Diabetes Care 26:1251–1257PubMed Bonora E, Kiechl S, Willeit J et al (2003) Carotid atherosclerosis and coronary heart disease in the metabolic syndrome: prospective data from the Bruneck study. Diabetes Care 26:1251–1257PubMed
22.
Zurück zum Zitat Hunt KJ, Resendez RG, Williams K, Haffner SM, Stern MP (2004) National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study. Circulation 110:1251–1257PubMedCrossRef Hunt KJ, Resendez RG, Williams K, Haffner SM, Stern MP (2004) National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study. Circulation 110:1251–1257PubMedCrossRef
23.
Zurück zum Zitat Isomaa B, Almgren P, Tuomi T et al (2001) Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24:683–689PubMed Isomaa B, Almgren P, Tuomi T et al (2001) Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24:683–689PubMed
24.
Zurück zum Zitat Lakka HM, Laaksonen DE, Lakka TA et al (2002) The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288:2709–2716PubMedCrossRef Lakka HM, Laaksonen DE, Lakka TA et al (2002) The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288:2709–2716PubMedCrossRef
25.
Zurück zum Zitat Scuteri A, Najjar SS, Morrell CH, Lakatta EG (2005) The metabolic syndrome in older individuals: prevalence and prediction of cardiovascular events: the Cardiovascular Health Study. Diabetes Care 28:882–887PubMed Scuteri A, Najjar SS, Morrell CH, Lakatta EG (2005) The metabolic syndrome in older individuals: prevalence and prediction of cardiovascular events: the Cardiovascular Health Study. Diabetes Care 28:882–887PubMed
26.
Zurück zum Zitat Dekker JM, Girman C, Rhodes T et al (2005) Metabolic syndrome and 10-year cardiovascular disease risk in the Hoorn Study. Circulation 112:666–673PubMedCrossRef Dekker JM, Girman C, Rhodes T et al (2005) Metabolic syndrome and 10-year cardiovascular disease risk in the Hoorn Study. Circulation 112:666–673PubMedCrossRef
27.
Zurück zum Zitat Juutilainen A, Lehto S, Ronnemaa T, Pyorala K, Laakso M (2006) Proteinuria and metabolic syndrome as predictors of cardiovascular death in non-diabetic and type 2 diabetic men and women. Diabetologia 49:56–65PubMedCrossRef Juutilainen A, Lehto S, Ronnemaa T, Pyorala K, Laakso M (2006) Proteinuria and metabolic syndrome as predictors of cardiovascular death in non-diabetic and type 2 diabetic men and women. Diabetologia 49:56–65PubMedCrossRef
28.
Zurück zum Zitat Sundstrom J, Riserus U, Byberg L, Zethelius B, Lithell H, Lind L (2006) Clinical value of the metabolic syndrome for long term prediction of total and cardiovascular mortality: prospective, population based cohort study. Br Med J 332:878–882CrossRef Sundstrom J, Riserus U, Byberg L, Zethelius B, Lithell H, Lind L (2006) Clinical value of the metabolic syndrome for long term prediction of total and cardiovascular mortality: prospective, population based cohort study. Br Med J 332:878–882CrossRef
29.
Zurück zum Zitat Kurl S, Laukkanen JA, Niskanen L et al (2006) Metabolic syndrome and the risk of stroke in middle-aged men. Stroke 37:806–811PubMedCrossRef Kurl S, Laukkanen JA, Niskanen L et al (2006) Metabolic syndrome and the risk of stroke in middle-aged men. Stroke 37:806–811PubMedCrossRef
30.
Zurück zum Zitat Butler J, Rodondi N, Zhu Y et al (2006) Metabolic syndrome and the risk of cardiovascular disease in older adults. J Am Coll Cardiol 47:1595–1602PubMedCrossRef Butler J, Rodondi N, Zhu Y et al (2006) Metabolic syndrome and the risk of cardiovascular disease in older adults. J Am Coll Cardiol 47:1595–1602PubMedCrossRef
31.
Zurück zum Zitat Jeppesen J, Hansen TW, Rasmussen S, Ibsen H, Torp-Pedersen C (2006) Metabolic syndrome, low-density lipoprotein cholesterol, and risk of cardiovascular disease: a population-based study. Atherosclerosis [Epub ahead of print] Jeppesen J, Hansen TW, Rasmussen S, Ibsen H, Torp-Pedersen C (2006) Metabolic syndrome, low-density lipoprotein cholesterol, and risk of cardiovascular disease: a population-based study. Atherosclerosis [Epub ahead of print]
32.
Zurück zum Zitat Katzmarzyk PT, Church TS, Blair SN (2004) Cardiorespiratory fitness attenuates the effects of the metabolic syndrome on all-cause and cardiovascular disease mortality in men. Arch Intern Med 164:1092–1097PubMedCrossRef Katzmarzyk PT, Church TS, Blair SN (2004) Cardiorespiratory fitness attenuates the effects of the metabolic syndrome on all-cause and cardiovascular disease mortality in men. Arch Intern Med 164:1092–1097PubMedCrossRef
33.
Zurück zum Zitat McNeill AM, Rosamond WD, Girman CJ et al (2005) The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. Diabetes Care 28:385–390PubMed McNeill AM, Rosamond WD, Girman CJ et al (2005) The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. Diabetes Care 28:385–390PubMed
34.
Zurück zum Zitat Onat A, Ceyhan K, Basar O, Erer B, Toprak S, Sansoy V (2002) Metabolic syndrome: major impact on coronary risk in a population with low cholesterol levels—a prospective and cross-sectional evaluation. Atherosclerosis 165:285–292PubMedCrossRef Onat A, Ceyhan K, Basar O, Erer B, Toprak S, Sansoy V (2002) Metabolic syndrome: major impact on coronary risk in a population with low cholesterol levels—a prospective and cross-sectional evaluation. Atherosclerosis 165:285–292PubMedCrossRef
35.
Zurück zum Zitat Resnick HE, Jones K, Ruotolo G et al (2003) Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease in nondiabetic American Indians: the Strong Heart Study. Diabetes Care 26:861–867PubMed Resnick HE, Jones K, Ruotolo G et al (2003) Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease in nondiabetic American Indians: the Strong Heart Study. Diabetes Care 26:861–867PubMed
36.
Zurück zum Zitat Rutter MK, Meigs JB, Sullivan LM, D’Agostino RB Sr, Wilson PW (2004) C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study. Circulation 110:380–385PubMedCrossRef Rutter MK, Meigs JB, Sullivan LM, D’Agostino RB Sr, Wilson PW (2004) C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study. Circulation 110:380–385PubMedCrossRef
37.
Zurück zum Zitat Takeuchi H, Saitoh S, Takagi S et al (2005) Metabolic syndrome and cardiac disease in Japanese men: applicability of the concept of metabolic syndrome defined by the National Cholesterol Education Program-Adult Treatment Panel III to Japanese men — the Tanno and Sobetsu Study. Hypertens Res 28:203–208PubMedCrossRef Takeuchi H, Saitoh S, Takagi S et al (2005) Metabolic syndrome and cardiac disease in Japanese men: applicability of the concept of metabolic syndrome defined by the National Cholesterol Education Program-Adult Treatment Panel III to Japanese men — the Tanno and Sobetsu Study. Hypertens Res 28:203–208PubMedCrossRef
38.
Zurück zum Zitat Ford ES (2004) The metabolic syndrome and mortality from cardiovascular disease and all-causes: findings from the National Health and Nutrition Examination Survey II Mortality Study. Atherosclerosis 173:309–314PubMedCrossRef Ford ES (2004) The metabolic syndrome and mortality from cardiovascular disease and all-causes: findings from the National Health and Nutrition Examination Survey II Mortality Study. Atherosclerosis 173:309–314PubMedCrossRef
39.
Zurück zum Zitat Liao Y, Kwon S, Shaughnessy S et al (2004) Critical evaluation of Adult Treatment Panel III criteria in identifying insulin resistance with dyslipidemia. Diabetes Care 27:978–983PubMed Liao Y, Kwon S, Shaughnessy S et al (2004) Critical evaluation of Adult Treatment Panel III criteria in identifying insulin resistance with dyslipidemia. Diabetes Care 27:978–983PubMed
Metadaten
Titel
Comparison of different definitions of the metabolic syndrome in relation to cardiovascular mortality in European men and women
verfasst von
Q. Qiao
The DECODE Study Group
Publikationsdatum
01.12.2006
Verlag
Springer-Verlag
Erschienen in
Diabetologia / Ausgabe 12/2006
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-006-0438-6

Weitere Artikel der Ausgabe 12/2006

Diabetologia 12/2006 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.